)

Lineage Cell Therapeutics (LCTX) investor relations material
Lineage Cell Therapeutics H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key announcements and pipeline updates
Announced new ILT1 initiative targeting type 1 diabetes, aiming to solve manufacturing scale challenges for islet cell therapy.
Hearing loss program partnered with William Demant Invest, securing multi-year development funding.
Lead program OpRegen for dry age-related macular degeneration is in Phase 2 with Roche and Genentech, under a $670M partnership.
Photoreceptor and undisclosed RND1 programs advanced, with IP unencumbered and new gene editing alliances formed.
Ongoing expansion into new indications, leveraging manufacturing expertise and strategic partnerships.
Clinical and manufacturing insights
OpRegen demonstrated durable anatomical and functional vision improvements in dry AMD, with effects persisting for years after a single administration.
Manufacturing platform enables scalable, pure cell production, critical for commercial viability and large-scale indications like diabetes.
Spinal cord injury program showed improved mobility and strong safety profile, with allogeneic, off-the-shelf cell therapy.
No cell rejection or tumor formation observed in long-term follow-up, reflecting advances in cell therapy safety and purity.
Manufacturing improvements have led to much purer cell populations, enhancing clinical outcomes and safety.
Strategic direction and future outlook
Focus on repeating success of lead program by applying platform to new therapeutic areas, moving from defensive to offensive strategy.
Partnerships are key to advancing early-stage programs and managing capital in a challenging biotech funding environment.
Ex vivo gene editing incorporated through new alliances, with rigorous analytical validation before patient administration.
Diabetes initiative aims to address the need for massive cell quantities, leveraging proprietary banking and differentiation modalities.
Company is investing in a long-term future, awaiting further data updates from ongoing clinical trials.
Next Lineage Cell Therapeutics earnings date

Next Lineage Cell Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage